Scarica l'app Stockscreener
3.33
2.06%
-0.07
Pre-mercato:
3.35
0.02
+0.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Agenus Inc Borsa (AGEN) Ultime notizie
New Phase II Data on BOT/BAL Combination in Gastroesophageal Cancer at AACR 2026Agenus - Oncodaily
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - msn.com
Buybacks Report: How sensitive is Agenus Inc to inflation2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Setup Watch: Can Agenus Inc deliver consistent EPS growth2026 Biggest Moves & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Weekly Earnings: Should you avoid Agenus Inc stock right nowPortfolio Performance Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Agenus receives $20M payment under Zydus Life Sciences collaboration - MSN
Everything Important About Agenus (AGEN) Receiving a Strong Buy Rating Upgrade - Bitget
Agenus unveils Phase II data for BOT BAL and MiNK iNKT therapy in PD-1 refractory cancer - Traders Union
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates? - Yahoo Finance
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy - Yahoo Finance
Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 - The AI Journal
HC Wainwright Analysts Boost Earnings Estimates for Agenus - MarketBeat
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - 뉴스와이어
Has Agenus (AGEN) Surpassed Other Healthcare Stocks So Far This Year? - Bitget
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance UK
Agenus (NASDAQ: AGEN) director awarded 2,448 Deferred Stock Units as board pay - stocktitan.net
Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer - BioPharma APAC
Portfolio Update: Is Agenus Inc benefiting from interest rate changes2026 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Agenus begins phase 3 trial for colorectal cancer treatment By Investing.com - Investing.com Australia
Agenus Enrolls First Patient in Phase 3 BATTMAN Trial for MSS/pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cance - GuruFocus
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cancer Treatment - GuruFocus
Agenus Inc Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial Of BOT Plus BAL Immunotherapy Combination In MSS Or PMMR Metastatic Colorectal Cancer - marketscreener.com
Can Agenus' BOT + BAL Immunotherapy Turn Cold Tumors Hot? - RTTNews
Agenus Launches Landmark Global Phase 3 Clinical Trial - Intellectia AI
Agenus begins phase 3 trial for colorectal cancer treatment - Investing.com
Agenus starts global colorectal cancer study for patients with few options - stocktitan.net
Agenus AGM: Bot/Bal Combo Targets “Cold” MSS Colorectal Cancer as Phase III BATMAN Trial Launches - Yahoo Finance
Agenus announced that the first patient has been enrolled in its global Phase III Battman trial. - Bitget
Agenus (NASDAQ:AGEN) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Webcast on Clinical Progress and Global Access Initiatives Set for March 31 – Agenus - oncodaily.com
Agenus Cervical Cancer Trial Terminated: What RaPiDS Means for AGEN Investors - tipranks.com
Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Agenus Securities Class Action Dismissed, Legal Risks Ease - tipranks.com
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access - BioSpace
Agenus Q4 2025 earnings preview - MSN
[SCHEDULE 13G/A] AGENU... - Stock Titan
Agenus reports dismissal of securities class action lawsuit in Massachusetts By Investing.com - Investing.com South Africa
Agenus reports dismissal of securities class action lawsuit in Massachusetts - Investing.com
Agenus wins dismissal of securities class action in Massachusetts federal court - TradingView
Court dismisses Agenus (AGEN) securities class action, siding with executives - Stock Titan
Agenus Secures Dismissal of Investors’ Cancer Drug Class Action - Bloomberg Law News
Agenus Escapes Investor Fraud Suit Over Cancer Drug - Law360
Agenus (NASDAQ: AGEN) director Armen paid salary in stock grant - Stock Titan
AGEN Technical Analysis | Trend, Signals & Chart Patterns | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus (NASDAQ:AGEN) Rating Increased to Buy at Wall Street Zen - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):